Medical therapies for eosinophilic esophagitis have targeted esophageal inflammation broadly (corticosteroids), or targeted biologic mediators, including anti‐IL5 (mepolizumab, reslizumab), anti‐IgE (omalizumab), anti‐IL4r (dupilumab), anti‐IL13 (RPC4046, alias cendakimab; QAX576, alias dectrekumab), and anti‐sialic acid binding Ig‐like lectin 8 (lirentelimab) (Nhu 2022). Here, IL5 is linked to eosinophilic esophagitis.